Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a ...

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCCUpdated data from ongoing Phase 1/1b trial in 1L ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.